IM Cannabis Corp. (NASDAQ:IMCC – Free Report) – Equities research analysts at Roth Capital reduced their Q3 2024 earnings per share estimates for IM Cannabis in a research report issued on Thursday, August 15th. Roth Capital analyst S. Fortune now expects that the company will post earnings per share of ($1.36) for the quarter, down from their prior estimate of ($0.90). The consensus estimate for IM Cannabis’ current full-year earnings is ($4.32) per share. Roth Capital also issued estimates for IM Cannabis’ Q4 2024 earnings at ($1.15) EPS, FY2024 earnings at ($5.61) EPS, Q1 2025 earnings at ($0.93) EPS, Q2 2025 earnings at ($0.68) EPS, Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($2.33) EPS.
IM Cannabis Stock Performance
Shares of IMCC opened at $2.77 on Monday. The company has a current ratio of 0.65, a quick ratio of 0.40 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $6.19 million, a price-to-earnings ratio of -0.58 and a beta of 0.47. The stock has a 50 day moving average of $2.70 and a 200 day moving average of $3.00. IM Cannabis has a 12 month low of $1.13 and a 12 month high of $8.10.
Institutional Trading of IM Cannabis
About IM Cannabis
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands.
Featured Stories
- Five stocks we like better than IM Cannabis
- Stock Analyst Ratings and Canadian Analyst Ratings
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Lowe’s Stock: Hold Now, Buy it When it Dips
- What is a Death Cross in Stocks?
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for IM Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IM Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.